Pull to refresh
Logo
GE HealthCare to acquire PET radiopharmaceutical maker Sofie Biosciences

GE HealthCare to acquire PET radiopharmaceutical maker Sofie Biosciences

Money Moves

The $945 million cash deal gives GE control of U.S. production and distribution of short-lived PET imaging drugs.

3 days ago: GE HealthCare announces $945M Sofie deal

Overview

Updated Yesterday

GE HealthCare agreed to buy Sofie Biosciences, a U.S. manufacturer of radioactive imaging drugs, for $945 million in cash. The deal adds 15 manufacturing sites and 21 cyclotrons that produce F18-labeled tracers used in positron emission tomography (PET) scans.

The prize is the "final mile" of radiopharmaceutical supply. F18 tracers decay on a 110-minute half-life, so production, distribution, and patient access are tightly coupled. The deal also hands GE U.S. rights to FAPI-74, a Phase III experimental tracer being tested across multiple cancer types.

Why it matters

PET drugs decay within two hours of production, so U.S. manufacturing control equals patient access. GE just bought the largest independent network.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$945M
Cash purchase price
Definitive agreement announced October 2026; closing expected in the first half of 2027.
21
Cyclotrons across 15 U.S. sites
Sofie's contract manufacturing network, plus one theranostics-focused development site.
110 minutes
Half-life of F18 tracers
The short decay window makes production location and distribution speed critical.
$2.9B
GE HealthCare's PDx segment revenue
Pharmaceutical Diagnostics revenue last year; the segment will absorb Sofie at closing.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2008 October 2026

5 events Latest: 3 days ago
Tap a bar to jump to that date
  1. GE HealthCare announces $945M Sofie deal

    Latest M&A

    GE HealthCare announces a definitive agreement to acquire Sofie Biosciences from Trilantic North America for $945 million in cash, with closing expected in the first half of 2027.

  2. Financial Times reports Sofie is for sale

    Report

    The Financial Times reports the forthcoming sale of Sofie Biosciences, citing unidentified sources familiar with the deal.

  3. FDA approves GE's Flyrcado

    Regulatory

    The Food and Drug Administration approves flurpiridaz F18 injection for detecting coronary artery disease and heart attacks. Sofie later becomes a manufacturer of the product.

  4. Trilantic takes stake in Sofie

    Investment

    Trilantic North America acquires roughly a 26% stake in Sofie, valuing the company at up to $550 million, per the Financial Times.

  5. Sofie Biosciences founded

    Founding

    The company is founded in Dulles, Virginia, and grows into a U.S. contract manufacturer of PET radiopharmaceuticals.

Scenarios

1

GE HealthCare completes Sofie acquisition in first half of 2027

Likely Resolves by Q2 2027

Discussed by: GE HealthCare management and BTIG analyst Ryan Zimmerman

Both parties say closing is expected in the first half of 2027, subject to regulatory approval. Zimmerman said the added manufacturing and distribution capacity could reduce bottlenecks in the radiopharmaceutical adoption cycle. Absent a regulatory objection, the deal likely closes around mid-2027 and Sofie continues operating as an independent manufacturer for its existing customers.

2

Regulatory review delays closing past mid-2027

Unlikely Resolves by End of 2027

Discussed by: Standard antitrust review risk; no specific analyst cited

Antitrust review by the Federal Trade Commission or Department of Justice could stretch beyond the expected window. No concerns have been raised publicly, but large healthcare deals often face extended review. If the review drags on, closing slips into late 2027 or beyond.

3

FAPI-74 posts positive Phase III data, advancing toward FDA filing

Possible Resolves by Q2 2028

Discussed by: GE HealthCare and Sofie as co-developers

FAPI-74 is in Phase III testing as a diagnostic for pancreatic cancer and gastroesophageal tumors, targeting fibroblast activation protein across multiple cancer types. Positive data would give GE a first-to-market pan-cancer PET tracer in the U.S. and, under its existing ex-U.S. rights, globally. It would also validate the $945 million price tag.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

August 2026

Curium agrees to buy Lantheus (2026)

In August 2026, radiopharmaceutical company Curium struck a deal worth up to $8 billion to acquire Lantheus, a major maker of cardiac and cancer imaging agents. The deal followed GE's own move into radiopharma and signaled a wave of consolidation.

Then

The deal underscored how companies are racing to secure radiopharmaceutical supply and drug pipelines.

Now

It previews the competitive pressure GE now faces from rivals building scale in the same market.

Why this matters now

Both deals chase the same prize: control of radiopharmaceutical production and distribution as PET imaging and targeted therapy markets grow.

October 2023

Eli Lilly buys Point Biopharma (2023)

Eli Lilly agreed to acquire Point Biopharma, a developer of radioligand therapies for cancer, in a cash deal announced in October 2023. The purchase gave Lilly in-house radiopharmaceutical manufacturing and a pipeline of experimental treatments.

Then

The acquisition gave Lilly a foothold in radiopharmaceutical production and development.

Now

It helped spark the broader rush by drug and device companies into radiopharma in the years that followed.

Why this matters now

It illustrates the pattern behind GE's move: large players buying manufacturing capability rather than building it from scratch.

Sources

(11)